{
    "Trade/Device Name(s)": [
        "Freelite Human Kappa Free Kit for use on the SPApLus",
        "Freelite Human Kappa Kit for use on the SpaPLUS"
    ],
    "Submitter Information": "The Binding Site Group, Ltd.",
    "510(k) Number": "k120056",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DFH"
    ],
    "Summary Letter Date": "March 26, 2013",
    "Summary Letter Received Date": "March 28, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5550"
    ],
    "Regulation Name(s)": [
        "Immunoglobulin (light chain specific) immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "Kappa free light chains"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Binding Site SPApLus"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Freelite Human Kappa Free Kit for quantitation of kappa free light chains in serum and urine using the Binding Site SPApLus",
    "Indications for Use Summary": "Intended for quantitation of kappa free light chains in serum and urine to aid in diagnosis and monitoring of multiple myeloma, lymphocytic neoplasms, Waldenstr\u00f6m's macroglobulinaemia, AL amyloidosis, light chain deposition disease and connective tissue diseases such as SLE, in conjunction with other laboratory and clinical findings.",
    "fda_folder": "Immunology"
}